Lv31
368 积分 2023-10-08 加入
Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial
2小时前
待确认
Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES-009): a randomised phase 2/3 trial
2小时前
已关闭
Clinical Efficacy and Safety of First- or Second-Generation EGFR-TKIs after Osimertinib Resistance for EGFR Mutated Lung Cancer: A Prospective Exploratory Study
29天前
已完结
The promise of bispecific antibodies: Clinical applications and challenges
1个月前
已完结
中央型肺癌与肺动脉、上腔静脉及支气管关系的多层螺旋CT表现
1个月前
已完结
Unresectable stage III non-small-cell lung cancer: state of the art and challenges
1个月前
已关闭
Unresectable stage III non-small-cell lung cancer: state of the art and challenges
1个月前
已完结
可诱导共刺激分子与程序性死亡－1在重症肌无力患者外周血表达的研究
2个月前
已完结
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
3个月前
已完结
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
3个月前
已完结
皖公网安备34019202002308